

Breast Cancer: Update Bulletin #3

<https://marketpublishers.com/r/B2FC27DC39DEN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: B2FC27DC39DEN

Abstracts

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza (olaparib; AstraZeneca) for patients with metastatic BC with BRCA gene mutation; Pfizer's talazoparib EMBRACA Phase III data in patients with advanced or metastatic BC; as well as Syndax Pharmaceuticals announcing a collaboration with Genentech for a Phase Ib/II trial evaluating the combination of entinostat with Tecentriq (atezolizumab) in patients with second-line HR+/HER2-metastatic BC.

Business Questions:

How do KOLs view Lynparza's approval?

What do KOLs consider Lynparza's advantages/disadvantages?

According to KOLs, how will Lynparza be positioned?

How does talazoparib's safety/efficacy compare to Lynparza?

Does talazoparib have any advantages over Lynparza?

What do KOLs think of combining entinostat with Tecentriq (atezolizumab)?

Which entinostat combination trial holds the most promise? Why?

I would like to order

Product name: Breast Cancer: Update Bulletin #3

Product link: <https://marketpublishers.com/r/B2FC27DC39DEN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B2FC27DC39DEN.html>